Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Holdings Lifted by Mirador Capital Partners LP

Mirador Capital Partners LP boosted its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 141.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 203,829 shares of the biotechnology company's stock after purchasing an additional 119,300 shares during the quarter. Mirador Capital Partners LP owned about 0.19% of Rocket Pharmaceuticals worth $1,360,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Rhumbline Advisers grew its holdings in Rocket Pharmaceuticals by 8.4% in the 1st quarter. Rhumbline Advisers now owns 107,638 shares of the biotechnology company's stock valued at $718,000 after buying an additional 8,299 shares during the period. California State Teachers Retirement System grew its holdings in Rocket Pharmaceuticals by 5.5% in the 4th quarter. California State Teachers Retirement System now owns 63,637 shares of the biotechnology company's stock valued at $800,000 after buying an additional 3,344 shares during the period. Toronto Dominion Bank purchased a new stake in Rocket Pharmaceuticals in the 4th quarter valued at about $13,827,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Rocket Pharmaceuticals by 16.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,572 shares of the biotechnology company's stock valued at $1,754,000 after buying an additional 19,939 shares during the period. Finally, Woodline Partners LP grew its holdings in Rocket Pharmaceuticals by 8.5% in the 4th quarter. Woodline Partners LP now owns 652,421 shares of the biotechnology company's stock valued at $8,201,000 after buying an additional 51,358 shares during the period. Institutional investors and hedge funds own 98.39% of the company's stock.

Insider Activity at Rocket Pharmaceuticals

In related news, insider Kinnari Patel bought 21,099 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average price of $4.70 per share, for a total transaction of $99,165.30. Following the transaction, the insider now directly owns 26,774 shares of the company's stock, valued at approximately $125,837.80. This represents a 371.79% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Aaron Ondrey sold 7,489 shares of the stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $5.29, for a total transaction of $39,616.81. Following the completion of the transaction, the chief financial officer now owns 129,650 shares of the company's stock, valued at $685,848.50. This represents a 5.46% decrease in their position. The disclosure for this sale can be found here. Company insiders own 24.76% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. BMO Capital Markets decreased their target price on Rocket Pharmaceuticals from $30.00 to $8.00 and set an "outperform" rating for the company in a report on Wednesday, May 28th. Scotiabank decreased their target price on Rocket Pharmaceuticals from $51.00 to $19.00 and set a "sector outperform" rating for the company in a report on Wednesday, May 28th. Wedbush reiterated an "outperform" rating and set a $32.00 target price on shares of Rocket Pharmaceuticals in a report on Friday, May 16th. Chardan Capital decreased their target price on Rocket Pharmaceuticals from $46.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, May 28th. Finally, Leerink Partnrs cut Rocket Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $19.57.

Rocket Pharmaceuticals Stock Performance

NASDAQ RCKT traded down $0.07 during trading hours on Thursday, hitting $2.85. The company had a trading volume of 2,656,655 shares, compared to its average volume of 1,954,049. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $2.19 and a fifty-two week high of $26.98. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $5.91 and a 200-day simple moving average of $9.24. The firm has a market cap of $304.34 million, a P/E ratio of -1.04 and a beta of 1.02.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.02. During the same period last year, the business earned ($0.66) earnings per share. Equities analysts predict that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current year.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.